Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS

Executive Summary

The Centers for Medicare and Medicaid Services has officially notified its contractors to stop using an option to limit payments for Medicare Part B drugs to the "least costly alternative" in a therapeutic class
Advertisement

Related Content

Reimbursement Briefs: Medicare Part B, PCORI Research
MedPAC Seeks Stakeholder Input On Medicare “Least Costly Alternative” Policy
Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Avastin v. Lucentis: An Early Test Case For Medicare ACOs
CER Will Accelerate Copay Incentives In Private Coverage, United Exec Says
CER Will Accelerate Copay Incentives In Private Coverage, United Exec Says
Amending IPAB: Lack Of Administrative, Judicial Review Raises Concern
Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?
Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?

Topics

Advertisement
UsernamePublicRestriction

Register

PS052213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel